Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04242095 · ClinicalTrials.gov registry record
Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effects
A clinical trial of Malignancy, sponsored by Alliance for Clinical Trials in Oncology.
- Recruiting
- Registry status
- 240
- Enrollment target
- 20
- Study locations
NCT04242095: Recruiting study of Malignancy, sponsored by Alliance for Clinical Trials in Oncology.
NCT04242095 is a study of Malignancy that is actively recruiting participants, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 240 participants, below the 12,557-participant average among 8 other Malignancy trials with a reported enrollment target (98% lower). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04242095, a study of Malignancy, is actively recruiting participants, sponsored by Alliance for Clinical Trials in Oncology.
- RECRUITING
- Registry status
- 240 participants
- Enrollment target
- 20
- Study locations
Study Summary
This trial collects research data and samples from patients who experience immunotherapy side effects to store for use in future research studies. Studying research data and samples from patients who experience immunotherapy side effects may help researchers better understand how to predict, prevent, and treat these side effects.
Primary Outcome
The objective of this study to establish a biorepository of biospecimen and clinical data. There is no primary clinical outcome for this study.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- OTHER Medical Chart Review
Study Locations (20)
Alaska
- Anchorage Associates in Radiation Medicine - Anchorage
- Anchorage Radiation Therapy Center - Anchorage
- Alaska Breast Care and Surgery LLC - Anchorage
- Alaska Oncology and Hematology LLC - Anchorage
- Alaska Women's Cancer Care - Anchorage
- Anchorage Oncology Centre - Anchorage
- Katmai Oncology Group - Anchorage
- Providence Alaska Medical Center - Anchorage
- Fairbanks Memorial Hospital - Fairbanks
California
- Mission Hope Medical Oncology - Arroyo Grande - Arroyo Grande
- PCR Oncology - Arroyo Grande
- Providence Saint Joseph Medical Center/Disney Family Cancer Center - Burbank
- Mercy Cancer Center - Carmichael - Carmichael
- Mercy San Juan Medical Center - Carmichael
Arizona
- Kingman Regional Medical Center - Kingman
- Cancer Center at Saint Joseph's - Phoenix
- Mayo Clinic Hospital in Arizona - Phoenix
Arkansas
- Mercy Hospital Fort Smith - Fort Smith
- CHI Saint Vincent Cancer Center Hot Springs - Hot Springs
- CARTI Cancer Center - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2020-03-12 |
| Est. Completion | 2026-10-01 |
What NCT04242095 shows while recruiting
NCT04242095 is an observational study that tracks outcomes without assigning an intervention. The registered 240 participants enrollment target is mid-sized for trials with a published cap, below the 12,557-participant average among 8 other Malignancy trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Malignancy appearing as the primary indexed condition, and to 2 interventions - of which Biospecimen Collection is the first listed.
NCT04242095 names 20 study sites across 4 states, led by Alaska, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT04242095 about?
NCT04242095 is a clinical study titled "Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effects". This trial collects research data and samples from patients who experience immunotherapy side effects to store for use in future research studies. Studying research data and samples from patients who experience immunotherapy side effects may help researchers better understand how to predict, prevent...
What is the current status of trial NCT04242095?
This trial is currently recruiting. The enrollment target is 240 participants. The study started on 2020-03-12. Estimated completion is 2026-10-01.
What conditions does trial NCT04242095 study?
This clinical trial studies the following conditions: Malignancy.
What interventions are being tested in trial NCT04242095?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Medical Chart Review (OTHER).
Who is sponsoring clinical trial NCT04242095?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04242095 being conducted?
This trial has 20 study locations across Alaska, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignancy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04242095's enrollment target sits among peer trials
240 2nd of 8 the highest of 8 other Malignancy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Malignancy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Novel Outreach Methods to Increase Enrollment to Early Phase Clinical Trials
RECRUITING · NA
-
Evaluating Informatics-assisted Immune-related Adverse Event Detection to Improve Registration Onto a Biorepository
RECRUITING · Phase 1
-
BostonGene-Integrated Genomic Registry (BIGR)
RECRUITING
-
Immuno-Oncology Database and Bioregistry
ACTIVE NOT RECRUITING
-
Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity
ACTIVE NOT RECRUITING · Phase 2
-
Feasibility Study of Intra-Tumoral Lipopolysaccharide Immunotherapy for Intra-Abdominal
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI